Literature DB >> 1538140

Real-time biospecific interaction analysis of antibody reactivity to peptides from the envelope glycoprotein, gp160, of HIV-1.

T C VanCott1, L D Loomis, R R Redfield, D L Birx.   

Abstract

A new assay designed to quantitate antibody reactivity to specific peptides using biospecific interaction analysis (BIAcore) has been developed. Peptides of various lengths (15-40 amino acids) and isoelectric points (pI = 4.5-13) were covalently linked (immobilized) to a biosensor and interacted with polyclonal human sera. The immobilization procedure was highly reproducible, with bound peptides retaining high antibody reactivity. The assay was rapid, requiring only 25-30 min to immobilize the peptide and 2-8 min for each subsequent peptide/serum binding interaction. The same peptide surface has been used for up to 90 cycles of serum binding and regeneration with only a 0.3% decay in reactivity over cycle number. The quantitative BIAcore signal, measuring peptide/antibody binding interactions, was directly related to the antigen/antibody concentrations within the biosensor. The assay allowed interactants to be studied in their native form and without the need of additional secondary detection antibodies. Correlation between conventional peptide ELISA and BIAcore was obtained. The BIAcore linear range persisted over a series of eight two-fold dilutions. This extended linear dynamic response range is an improvement over conventional ELISA measurements. The sensitivity for monoclonal antibody detection is similar to conventional ELISAs and 4.9 ng/ml was readily detected.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1538140     DOI: 10.1016/0022-1759(92)90225-i

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  8 in total

Review 1.  Current methods for detecting antibodies against erythropoietin and other recombinant proteins.

Authors:  Robin Thorpe; Steven J Swanson
Journal:  Clin Diagn Lab Immunol       Date:  2005-01

2.  Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12.

Authors:  J R Mascola; M K Louder; T C VanCott; C V Sapan; J S Lambert; L R Muenz; B Bunow; D L Birx; M L Robb
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

3.  Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160.

Authors:  T C VanCott; J R Mascola; R W Kaminski; V Kalyanaraman; P L Hallberg; P R Burnett; J T Ulrich; D J Rechtman; D L Birx
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

4.  The retinitis pigmentosa GTPase regulator, RPGR, interacts with the delta subunit of rod cyclic GMP phosphodiesterase.

Authors:  M Linari; M Ueffing; F Manson; A Wright; T Meitinger; J Becker
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

5.  Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro.

Authors:  T B McNeely; M Dealy; D J Dripps; J M Orenstein; S P Eisenberg; S M Wahl
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

6.  Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.

Authors:  P Roben; J P Moore; M Thali; J Sodroski; C F Barbas; D R Burton
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

7.  Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans.

Authors:  J P Moore; D D Ho
Journal:  J Virol       Date:  1993-02       Impact factor: 5.103

8.  Determination of affinities of a panel of IgGs and Fabs for whole enveloped (influenza A) virions using surface plasmon resonance.

Authors:  D J Schofield; N J Dimmock
Journal:  J Virol Methods       Date:  1996-10       Impact factor: 2.014

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.